Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis

Howard L. Weiner, Glenn A. Mackin, Makoto Matsui, E. John Orav, Samia J. Khoury, David M. Dawson, David A. Hafler

doi:10.1126/science.7680493

Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis

DOI Web Site 被引用文献6件

Howard L. Weiner

Center for Neurologic Diseases, Division of Neurology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.
Glenn A. Mackin

Center for Neurologic Diseases, Division of Neurology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.
Makoto Matsui

Center for Neurologic Diseases, Division of Neurology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.
E. John Orav

Harvard School of Public Health, Boston, MA 02115.
Samia J. Khoury

Center for Neurologic Diseases, Division of Neurology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.
David M. Dawson

Center for Neurologic Diseases, Division of Neurology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.
David A. Hafler

Center for Neurologic Diseases, Division of Neurology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.

抄録

<jats:p>Multiple sclerosis (MS) is thought to be an autoimmune disease mediated by T lymphocytes that recognize myelin components of the central nervous system. In a 1-year double-blind study, 30 individuals with relapsing-remitting MS received daily capsules of bovine myelin or a control protein to determine the effect of oral tolerization to myelin antigens on the disease. Six of 15 individuals in the myelin-treated group had at least one major exacerbation; 12 of 15 had an attack in the control group. T cells reactive with myelin basic protein were reduced in the myelin-treated group. No toxicity or side effects were noted. Although conclusions about efficacy cannot be drawn from these data, they open an area of investigation for MS and other autoimmune diseases.</jats:p>